666 related articles for article (PubMed ID: 24440208)
1. Adverse events following immunization in Ontario's female school-based HPV program.
Harris T; Williams DM; Fediurek J; Scott T; Deeks SL
Vaccine; 2014 Feb; 32(9):1061-6. PubMed ID: 24440208
[TBL] [Abstract][Full Text] [Related]
2. Adverse events following school-based vaccination of girls with quadrivalent human papillomavirus vaccine in Slovenia, 2009 to 2013.
Šubelj M; Učakar V; Kraigher A; Klavs I
Euro Surveill; 2016; 21(14):. PubMed ID: 27103551
[TBL] [Abstract][Full Text] [Related]
3. Adverse events following HPV vaccination, Alberta 2006-2014.
Liu XC; Bell CA; Simmonds KA; Svenson LW; Russell ML
Vaccine; 2016 Apr; 34(15):1800-5. PubMed ID: 26921782
[TBL] [Abstract][Full Text] [Related]
4. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.
Zhou W; Pool V; Iskander JK; English-Bullard R; Ball R; Wise RP; Haber P; Pless RP; Mootrey G; Ellenberg SS; Braun MM; Chen RT
MMWR Surveill Summ; 2003 Jan; 52(1):1-24. PubMed ID: 12825543
[TBL] [Abstract][Full Text] [Related]
5. Annual report: surveillance of adverse events following immunisation in Australia, 2007.
Lawrence G; Gold MS; Hill R; Deeks S; Glasswell A; McIntyre PB
Commun Dis Intell Q Rep; 2008 Dec; 32(4):371-87. PubMed ID: 19374268
[TBL] [Abstract][Full Text] [Related]
6. Surveillance of adverse events following immunisation: Australia 2002 to 2003.
Lawrence G; Boyd I; McIntyre P; Isaacs D
Commun Dis Intell Q Rep; 2004; 28(3):324-38. PubMed ID: 15574056
[TBL] [Abstract][Full Text] [Related]
7. Annual report: surveillance of adverse events following immunisation in Australia, 2004.
Lawrence GL; Boyd I; McIntyre PB; Isaacs D
Commun Dis Intell Q Rep; 2005; 29(3):248-62. PubMed ID: 16220860
[TBL] [Abstract][Full Text] [Related]
8. Annual report: Surveillance of adverse events following immunisation in Australia, 2005.
Lawrence G; Boyd I; McIntyre P; Isaacs D
Commun Dis Intell Q Rep; 2006; 30(3):319-33. PubMed ID: 17120485
[TBL] [Abstract][Full Text] [Related]
9. Monitoring adverse events following immunisation in developing countries: experience from human papillomavirus vaccination demonstration projects.
Jain KM; Paul P; LaMontagne DS
Sex Health; 2013 Mar; 10(1):57-63. PubMed ID: 23237538
[TBL] [Abstract][Full Text] [Related]
10. Annual report: surveillance of adverse events following immunisation in Australia, 2008.
Menzies R; Mahajan D; Gold MS; Roomiani I; McIntyre P; Lawrence G
Commun Dis Intell Q Rep; 2009 Dec; 33(4):365-81. PubMed ID: 20301966
[TBL] [Abstract][Full Text] [Related]
11. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015.
Arana JE; Harrington T; Cano M; Lewis P; Mba-Jonas A; Rongxia L; Stewart B; Markowitz LE; Shimabukuro TT
Vaccine; 2018 Mar; 36(13):1781-1788. PubMed ID: 29477308
[TBL] [Abstract][Full Text] [Related]
12. Surveillance of adverse events following immunisation: Australia, 2000-2002.
Lawrence G; Menzies R; Burgess M; McIntyre P; Wood N; Boyd I; Purcell P; Isaacs D
Commun Dis Intell Q Rep; 2003; 27(3):307-23. PubMed ID: 14510057
[TBL] [Abstract][Full Text] [Related]
13. Annual report on surveillance of adverse events following immunisation in Australia, 2006.
Lawrence GL; Aratchige PE; Boyd I; McIntyre PB; Gold MS
Commun Dis Intell Q Rep; 2007 Sep; 31(3):269-82. PubMed ID: 17974219
[TBL] [Abstract][Full Text] [Related]
14. Adverse events following Quadrivalent HPV vaccination reported in Sao Paulo State, Brazil, in the first three years after introducing the vaccine for routine immunization (March 2014 to December 2016).
Mauro AB; Fernandes EG; Miyaji KT; Arantes BA; Valente MG; Sato HK; Sartori AMC
Rev Inst Med Trop Sao Paulo; 2019 Sep; 61():e43. PubMed ID: 31531621
[TBL] [Abstract][Full Text] [Related]
15. Annual report: Surveillance of adverse events following immunisation in Australia, 2011.
Mahajan D; Cook J; Dey A; Macartney K; Menzies RI
Commun Dis Intell Q Rep; 2012 Dec; 36(4):E315-32. PubMed ID: 23330706
[TBL] [Abstract][Full Text] [Related]
16. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine.
Slade BA; Leidel L; Vellozzi C; Woo EJ; Hua W; Sutherland A; Izurieta HS; Ball R; Miller N; Braun MM; Markowitz LE; Iskander J
JAMA; 2009 Aug; 302(7):750-7. PubMed ID: 19690307
[TBL] [Abstract][Full Text] [Related]
17. Coverage from Ontario, Canada's school-based HPV vaccine program: the first three years.
Wilson SE; Harris T; Sethi P; Fediurek J; Macdonald L; Deeks SL
Vaccine; 2013 Jan; 31(5):757-62. PubMed ID: 23246265
[TBL] [Abstract][Full Text] [Related]
18. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink.
Gee J; Naleway A; Shui I; Baggs J; Yin R; Li R; Kulldorff M; Lewis E; Fireman B; Daley MF; Klein NP; Weintraub ES
Vaccine; 2011 Oct; 29(46):8279-84. PubMed ID: 21907257
[TBL] [Abstract][Full Text] [Related]
19. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine.
Block SL; Brown DR; Chatterjee A; Gold MA; Sings HL; Meibohm A; Dana A; Haupt RM; Barr E; Tamms GM; Zhou H; Reisinger KS
Pediatr Infect Dis J; 2010 Feb; 29(2):95-101. PubMed ID: 19952863
[TBL] [Abstract][Full Text] [Related]
20. Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case-control assessment of the vaccine adverse event reporting system (VAERS) database.
Geier DA; Geier MR
Immunol Res; 2017 Feb; 65(1):46-54. PubMed ID: 27406735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
